Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Clearside Biomedical ( (CLSD) ) just unveiled an announcement.
On July 17, 2025, Clearside Biomedical announced it is exploring strategic alternatives to enhance shareholder value, including the sale or license of assets, partnerships, or mergers. To conserve resources, all employees, including top executives, will transition to consulting roles, and internal R&D programs will be paused. The company has retained Piper Sandler to assist in this strategic evaluation process. This move comes amid challenging economic conditions and aims to advance Clearside’s proprietary suprachoroidal delivery platform and ophthalmology pipeline. The workforce reduction is expected to incur charges of approximately $3.4 million in the third quarter of 2025.
The most recent analyst rating on (CLSD) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Clearside Biomedical stock, see the CLSD Stock Forecast page.
Spark’s Take on CLSD Stock
According to Spark, TipRanks’ AI Analyst, CLSD is a Neutral.
Clearside Biomedical’s overall stock score is heavily impacted by its poor financial performance and valuation risks. Despite some technical stabilization, the lack of revenue and consistent losses pose significant challenges.
To see Spark’s full report on CLSD stock, click here.
More about Clearside Biomedical
Clearside Biomedical, Inc. is a biopharmaceutical company focused on revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®). The company’s primary product is the SCS Microinjector®, which enables a non-surgical procedure for targeting therapies to the macula, retina, or choroid. Clearside is developing a pipeline of small molecule product candidates, including CLS-AX for treating neovascular age-related macular degeneration.
Average Trading Volume: 233,446
Technical Sentiment Signal: Sell
Current Market Cap: $64.3M
For a thorough assessment of CLSD stock, go to TipRanks’ Stock Analysis page.